has_participant has participant teatment with COVID-19 Convalescent Plasma teatment with CCP https://www.fda.gov/media/141480/download https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-convalescent-plasma-potential-promising-covid-19-treatment Oliver He, Yingtong Liu, Anthony Huffman COVID-19 Convalescent Plasma (CCP) is proposed for use under an Emergency Use Authorization (EUA) under section 564 of the Federal Food, Drug, and Cosmetic Act (the Act),(21 USC 360bbb-3) as a passive immune therapy for the treatment of hospitalized patients with COVID-19. COVID-19 Convalescent Plasma authorized COVID-19 teatment